Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 8/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | KDR | P35968 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.56 |
| ▸ | IDH1 | O75874 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.55 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17079632 | 0.87 | DDX3X (0.73) | GRIK1MEN1KMT2AMAPTHTT | |
| SCHEMBL26417440 | 0.84 | TRPV1 (0.63) | GRIK1MEN1KMT2AMAPTHTT | |
| SCHEMBL17664319 | 0.82 | KMT2A (0.82) | GRIK1MEN1KMT2AMAPTHTT | |
| SCHEMBL6500776 | 0.82 | DDX3X (0.64) | MEN1KMT2AMAPTHTTRAB9A | |
| SCHEMBL29470036 | 0.82 | KMT2A (0.67) | GRIK1MEN1KMT2AMAPTHTT | |
| SCHEMBL10966834 | 0.81 | GAA (0.76) | MEN1KMT2AMAPTHTTRAB9A | |
| SCHEMBL5597699 | 0.81 | KMT2A (0.90) | GRIK1MEN1KMT2AMAPTHTT | |
| SCHEMBL30101230 | 0.81 | KMT2A (0.90) | GRIK1MEN1KMT2AMAPTHTT | |
| SCHEMBL19398194 | 0.81 | KDR (0.70) | GRIK1MEN1KMT2AMAPTHTT | |
| SCHEMBL1463217 | 0.81 | GRIK1 (1.00) | GRIK1MEN1KMT2AMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663192-B1 | hERG1 CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | NEUROSEARCH AS (DK) | 2008-12-03 | — | — | EP | claimed |
| US-20060281794-A1 | Erg channel openers for the treatment of cardiac arrhythmias | NEUROSEARCH A/S (DK) | 2006-12-14 | — | — | US | claimed |
| CN-1845726-A | Erg channel openers for the treatment of cardiac arrhythmias | POSEIDON PHARMACEUTICALS AS (DK) | 2006-10-11 | — | — | CN | claimed |
| EP-1663192-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | Poseidon Pharmaceuticals A/S (DK) | 2006-06-07 | — | — | EP | claimed |
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | claimed |
| WO-2005023237-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-03-17 | — | — | WO | claimed |
| US-20110071164-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | OLESEN SOEREN PETER | 2011-03-24 | — | — | US | disclosed |
| US-7851492-B2 | ERG channel openers for the treatment of cardiac arrhythmias | NEUROSEARCH A/S (DK) | 2010-12-14 | — | — | US | disclosed |
| EP-1663192-B1 | hERG1 CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | NEUROSEARCH AS (DK) | 2008-12-03 | — | — | EP | disclosed |
| US-20060281794-A1 | Erg channel openers for the treatment of cardiac arrhythmias | NEUROSEARCH A/S (DK) | 2006-12-14 | — | — | US | disclosed |
| CN-1845726-A | Erg channel openers for the treatment of cardiac arrhythmias | POSEIDON PHARMACEUTICALS AS (DK) | 2006-10-11 | — | — | CN | disclosed |
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | disclosed |
| WO-2005023238-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF HYPEREXCITABILITY-RELATED NEURONAL DISEASES | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281794-A1 | Erg channel openers for the treatment of cardiac arrhythmias | KCNJ2, KCNN3, KCNE1 | GRIK1 622/4885MEN1 2084/4885KMT2A 2189/4885 |
| US-20110071164-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | KCNJ2, KCNN3, KCNE1 | GRIK1 622/4885MEN1 2084/4885KMT2A 2189/4885 |
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | CPA3, HNMT, CMA1 | GRIK1 655/4885MEN1 903/4885KMT2A 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.